Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Sperm Epigenome in Hodgkin Lymphoma [NA]
This entry notes a clinical trial investigating the sperm epigenome in patients with Hodgkin lymphoma, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE [Phase 1]
Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes (GRALE) for EBV-positive lymphomas, currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma
A clinical trial update notes that a study evaluating therapeutic recommendations for children with Hodgkin lymphoma is currently recruiting…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies [Phase 2]
Phase 2 clinical trial update describing a donor stem cell transplant conditioning regimen with treosulfan, fludarabine, and total-body irra…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Impact of Respiratory Training in Lymphoma Survivors [NA]
A terminated clinical trial evaluating respiratory training in lymphoma survivors has posted results as of 2026-02-27. The study was sponsor…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pedia…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies [Phase 1, Phase 2]
A first-in-human study evaluating HLA partially to fully matched allogeneic, cryopreserved deceased donor bone marrow transplantation for va…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
An ongoing study by the Children's Oncology Group investigates how patterns of blood cell growth relate to heart health after treatment for …
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India [Phase 4]
A Phase 4 clinical trial in India evaluating brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine for adults with Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) [Phase 2]
This update presents safety and efficacy data from a Phase 2 study of pembrolizumab (Keytruda) in children and young adults with classical H…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) [Phase 3]
This update reports the completion of a Phase 3 trial (MK-3475-204/KEYNOTE-204) comparing pembrolizumab to brentuximab vedotin in relapsed o…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant [Phase 2]
A Phase 2 clinical trial update evaluating busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in patients with hematologi…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating A(B)VD chemotherapy followed by Nivolumab as frontline therapy for higher-risk classical Hodgkin lymph…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
Update on a clinical study examining myocardial tissue injury and heart function in survivors of Hodgkin lymphoma.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL [Phase 2]
A Phase II trial evaluating the combination of pembrolizumab and all-trans retinoic acid for relapsed or refractory Hodgkin lymphoma and non…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL [Phase 3]
This entry notes the completion of a Phase 3 trial investigating a treatment strategy driven by early PET response in Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma [Phase 1]
A Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes engineered to express a CD30 chimeric receptor for CD30-positive Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the safety and efficacy of combining favezelimab (MK-4280) with pembrolizumab (MK-3475) in patients wi…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab plus brentuximab vedotin versus GDP chemotherapy with stem cell transplant for relapsed/re…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Lifestyle Intervention of Food and Exercise for Lymphoma Survivors [NA]
A University of Miami-led clinical trial evaluating a lifestyle intervention involving diet and exercise for lymphoma survivors is currently…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies [Phase 1]
A Phase 1 trial evaluating flotetuzumab for relapsed or refractory CD123-positive hematologic malignancies has completed, providing initial …
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Prognostic Model of Elderly Hodgkin Lymphoma in China
Update on a prognostic model study for elderly Hodgkin Lymphoma patients in China, sponsored by Tianjin Medical University Cancer Institute …
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients [Phase 1, Phase 2]
A multicenter Phase 1/2 clinical trial is evaluating the combination of atezolizumab with the BEGEV chemotherapy regimen for relapsed or ref…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers [Phase 1]
A Phase 1 safety study of PF-08046045/SGN-35T sponsored by Seagen has been terminated in adults with advanced lymphomas and Hodgkin disease.
-
CLINICAL_TRIALS trial_result · 2026-01-20Clinical Trial Update: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) [Phase 2]
A Phase 2 trial comparing coformulated favezelimab/pembrolizumab to physician's choice chemotherapy in PD-(L)1-refractory classical Hodgkin …